ISIN | LU0432979614 |
---|---|
Valor Number | 10261626 |
Bloomberg Global ID | |
Fund Name | JPM Global Healthcare Fund A acc USD |
Fund Provider |
JPMorgan Asset Management (Switzerland) LLC
Dreikönigstrasse 37 Postfach 8022 Zürich Tel. +41 (0)44 206 86 00 |
Fund Provider | JPMorgan Asset Management (Switzerland) LLC |
Representative in Switzerland |
JPMorgan Asset Management (Switzerland) LLC Genève Phone: +41 22 744 11 11 |
Distributor(s) |
JP Morgan Asset Management (Europe) Sàrl Senningerberg Phone: +352 34 10 1 |
Asset Class | Equities |
EFC Category | Equity Health Care |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | Combination of issuing commission charged by the fund management company and transaction fee charged by the fund |
Redemption Condition | Combination of redemption commission charged by the fund management company and transaction fee charged by the fund |
Investment Strategy *** | To achieve a return by investing primarily in pharmaceutical, biotechnology, healthcare services, medical technology and life sciences companies ("Healthcare Companies"), globally. |
Peculiarities |
Current Price * | 551.21 USD | 16.09.2024 |
---|---|---|
Previous Price * | 548.00 USD | 13.09.2024 |
52 Week High * | 557.48 USD | 03.09.2024 |
52 Week Low * | 417.30 USD | 30.10.2023 |
NAV * | 551.21 USD | 16.09.2024 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 4,512,247,934 | |
Unit/Share Assets *** | 1,220,363,116 | |
Trading Information SIX |
YTD Performance | +14.83% |
29.12.2023 - 16.09.2024
29.12.2023 16.09.2024 |
---|---|---|
YTD Performance (in CHF) | +15.73% |
29.12.2023 - 16.09.2024
29.12.2023 16.09.2024 |
1 month | +1.82% |
16.08.2024 - 16.09.2024
16.08.2024 16.09.2024 |
3 months | +8.05% |
17.06.2024 - 16.09.2024
17.06.2024 16.09.2024 |
6 months | +8.49% |
18.03.2024 - 16.09.2024
18.03.2024 16.09.2024 |
1 year | +19.95% |
18.09.2023 - 16.09.2024
18.09.2023 16.09.2024 |
2 years | +21.23% |
16.09.2022 - 16.09.2024
16.09.2022 16.09.2024 |
3 years | +10.24% |
16.09.2021 - 16.09.2024
16.09.2021 16.09.2024 |
5 years | +65.98% |
16.09.2019 - 16.09.2024
16.09.2019 16.09.2024 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
UnitedHealth Group Inc | 9.26% | |
---|---|---|
Eli Lilly and Co | 9.25% | |
Novo Nordisk A/S Class B | 6.25% | |
AbbVie Inc | 5.55% | |
AstraZeneca PLC | 5.22% | |
Thermo Fisher Scientific Inc | 4.61% | |
Regeneron Pharmaceuticals Inc | 4.13% | |
Danaher Corp | 3.85% | |
Boston Scientific Corp | 2.86% | |
Sanofi SA | 2.41% | |
Last data update | 31.08.2024 |
TER *** | 1.70% |
---|---|
TER date *** | 31.12.2023 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 1.50% |
Ongoing Charges *** | 1.72% |
SRRI ***
|
|
SRRI date *** | 31.08.2024 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** | |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |